Contineum Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Contineum Therapeutics, Inc. (CTNM) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$42.26 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2025-03-06
- Contineum Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2024-12-31 was -$14.56M.
- Contineum Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2024-09-30 was -$10.27M.
- Contineum Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2024-06-30 was -$9.01M, a 405.49% decline year-over-year.
- Contineum Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2024-03-31 was -$8.42M.
- Contineum Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$42.26M, a 15522.63% decline from fiscal 2023.
- Contineum Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2023 was $274.00K.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$14.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$24.83M derived: sum of 2 quarters · filed 2025-03-06 | -$33.84M derived: sum of 3 quarters · filed 2025-03-06 | -$42.26M 10-K · filed 2025-03-06 |
| 2024-09-30 | -$10.27M 10-Q · filed 2024-11-06 | -$19.28M derived: sum of 2 quarters · filed 2024-11-06 | -$27.69M 10-Q · filed 2024-11-06 | -$28.89M derived: sum of 4 quarters · filed 2025-03-06 |
| 2024-06-30 | -$9.01M 10-Q · filed 2024-08-14 | -$17.43M 10-Q · filed 2024-08-14 | -$18.62M derived: sum of 3 quarters · filed 2025-03-06 | -$24.87M derived: sum of 4 quarters · filed 2025-03-06 |
| 2024-03-31 | -$8.42M derived: 10-K 12 month − 3 quarters · filed 2025-03-06 | -$9.61M derived: sum of 2 quarters · filed 2025-03-06 | -$15.87M derived: sum of 3 quarters · filed 2025-03-06 | -$12.92M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-12-31 | -$1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$7.45M derived: sum of 2 quarters · filed 2025-03-06 | -$4.50M derived: sum of 3 quarters · filed 2025-03-06 | $274.00K 10-K · filed 2025-03-06 |
| 2023-09-30 | -$6.25M 10-Q · filed 2024-11-06 | -$3.30M derived: sum of 2 quarters · filed 2024-11-06 | $1.47M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $2.95M 10-Q · filed 2024-08-14 | $2.60M 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |